Lecap Asset Management Ltd. Takes $300,000 Position in Organon & Co. (NYSE:OGN)

Lecap Asset Management Ltd. bought a new stake in Organon & Co. (NYSE:OGN) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 20,773 shares of the company’s stock, valued at approximately $300,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. New York State Teachers Retirement System boosted its stake in shares of Organon & Co. by 20.1% in the 4th quarter. New York State Teachers Retirement System now owns 348,226 shares of the company’s stock valued at $5,021,000 after purchasing an additional 58,321 shares in the last quarter. State of Alaska Department of Revenue lifted its position in Organon & Co. by 417.8% during the 4th quarter. State of Alaska Department of Revenue now owns 157,249 shares of the company’s stock worth $2,267,000 after buying an additional 126,882 shares in the last quarter. UBS Group AG lifted its position in Organon & Co. by 88.3% during the 3rd quarter. UBS Group AG now owns 657,912 shares of the company’s stock worth $11,421,000 after buying an additional 308,470 shares in the last quarter. Nordea Investment Management AB lifted its position in Organon & Co. by 2,016.0% during the 4th quarter. Nordea Investment Management AB now owns 3,128,810 shares of the company’s stock worth $44,648,000 after buying an additional 2,980,945 shares in the last quarter. Finally, Deutsche Bank AG lifted its position in Organon & Co. by 29.7% during the 3rd quarter. Deutsche Bank AG now owns 798,210 shares of the company’s stock worth $13,857,000 after buying an additional 182,822 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Trading Up 1.5 %

Shares of NYSE:OGN opened at $17.71 on Tuesday. The stock has a market capitalization of $4.53 billion, a P/E ratio of 4.43, a P/E/G ratio of 0.83 and a beta of 0.82. Organon & Co. has a 1-year low of $10.84 and a 1-year high of $24.79. The business has a 50-day moving average price of $17.92 and a two-hundred day moving average price of $15.59.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.14. The firm had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.55 billion. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. As a group, equities analysts predict that Organon & Co. will post 4.08 EPS for the current year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 14th. Stockholders of record on Monday, February 26th were paid a $0.28 dividend. The ex-dividend date was Friday, February 23rd. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.32%. Organon & Co.’s dividend payout ratio (DPR) is presently 28.00%.

Analyst Ratings Changes

Separately, The Goldman Sachs Group upped their price target on shares of Organon & Co. from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 20th.

Insider Activity

In related news, insider Kirke Weaver purchased 2,720 shares of the stock in a transaction dated Thursday, February 22nd. The stock was bought at an average cost of $18.36 per share, with a total value of $49,939.20. Following the purchase, the insider now directly owns 15,181 shares in the company, valued at approximately $278,723.16. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.17% of the stock is currently owned by company insiders.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.